Research is inseparable from treatment of the patients, it’s a building block since you cannot find a cure without a deep understanding what the disease is made of, its origins and why it becomes resistant to drugs”.
Dr. Talia Golan is a clinician-scientist currently conducting translational laboratory research while also serving as medical director of the Pancreatic Cancer Center at Sheba Medical Center, Israel. Her clinical interest is in patients with pancreatic cancer. Dr. Golan’s career goals include expertise in clinical medicine, translational laboratory research, and drug development. Dr. Golan is PI on multiple early-phase trials on immune modulators. Her clinical and research expertise focus on the understanding and treatment of hereditary PC and patient. Dr. Golan is co-global PI of the first biomarker-selected (BRCA) Phase III clinical trial in PC, the POLO study that led to FDA/EMA approval of olaparib in this subset (NEJM Golan et al 2019).
Dr. Golan’s translational research lab, focuses on improving the standard of care options for pancreatic cancer (PC) patients by finding targeted treatments tailored for each patient based on his own genetic background. Disease heterogeneity and late detection are still the main challenges of pancreatic cancer treatment.